MedTrace Logo

Antidepressants Trial in Parkinson's Disease

NCT03652870 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2023-05-06

No results posted yet for this study

Summary

This is a randomised trial in a NHS setting, comparing the clinical effectiveness and cost-effectiveness of the selective serotonin reuptake inhibitor, escitalopram, and of the tricyclic antidepressant, nortriptyline, to placebo, undertaken in a real-life setting in addition to standard psychological care for the treatment of patients with depression in Parkinson's disease. Participants will be randomly allocated 1:1:1 to receive escitalopram or nortriptyline or placebo.

Conditions

Interventions

DRUG

Nortriptyline

A medication used to treat conditions such as depression

DRUG

Escitalopram

A medication used to treat conditions such as depression

DRUG

Placebo

Lactose and magnesium stearate tablet to be used as a placebo.

Sponsors & Collaborators

  • London North West Healthcare NHS Trust

    collaborator OTHER

  • King's College London

    collaborator OTHER

  • University Hospital Plymouth NHS Trust

    collaborator OTHER

  • NHS Lothian

    collaborator OTHER_GOV

  • University College, London

    lead OTHER

Principal Investigators

  • Anette Schrag · University College, London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-05
Primary Completion
2023-01-23
Completion
2023-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03652870 on ClinicalTrials.gov